RxDoctor Payments Data

Roger Holt

Psychiatric/Mental Health · Lexington, NCNPI 1518143817

Payments from drug & device makers

$4,398in general payments, 2019–2025

Across 233 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$820
  • Neurocrine Biosciences, Inc.$699
  • AbbVie$444
  • Otsuka America Pharmaceutical, Inc.$408
  • Sunovion Pharmaceuticals Inc.$267
  • plus $637 from 8 others

What the payments were for

  • Food & beverage$4,14194%
  • Education$2586%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,398 in reported general payments places this provider in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$18,120
Medicare patients
96
Services billed
232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate94$793,395
Invega TrinzaPaliperidone Palmitate81$658,955
AustedoDeutetrabenazine52$390,932
Invega HafyeraPaliperidone Palmitate15$242,818
Invega SustennaPaliperidone Palmitate43$129,221
VraylarCariprazine Hcl59$109,853
FanaptIloperidone52$61,287
Austedo XrDeutetrabenazine11$54,636
Paliperidone ErPaliperidone129$26,166
Lurasidone Hcl92$25,228
TrintellixVortioxetine Hydrobromide37$21,349
VivitrolNaltrexone Microspheres12$16,286
Ziprasidone Hcl92$8,220
Aripiprazole121$7,363
Olanzapine211$6,590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$699$793,39594 claims
Johnson & JohnsonInvega Trinza, Invega Sustenna$157$788,176124 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Loxapine$820$446,85479 claims
AbbVieVraylar$444$109,85359 claims
Vanda Pharmaceuticals Inc.Fanapt$42$61,28752 claims
Alkermes, Inc.Vivitrol$1,124$16,28612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Lexington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →